Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06511648
Title	Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations (SOGUG-NEOWIN)
Acronym	SOGUG-NEOWIN
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Spanish Oncology Genito-Urinary Group
Indications	invasive bladder transitional cell carcinoma
Therapies	Cetrelimab + Erdafitinib Erdafitinib
Age Groups:	adult \| senior
Covered Countries	ITA \| GBR \| FRA \| ESP